SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Programmed death-ligand 1 (PD-L1) is a T-cell inhibitory checkpoint molecule that suppresses antitumor immunity. Anti-PD-L1 antibodies have shown remarkable promise in treating tumors, but the patient response rate is low. Therefore, small-molecule checkpoint inhibitors blocking PD-L1 function are urgently needed. METHODS: Changes of protein expression and phosphorylation levels were determined by immunoblotting. The level of Membrane PD-L1 was examined by flow cytometer. Cytotoxicity of T cells and NK cells toward tumor cells were detected using LDH and cell index assays. Lysosome function was investigated by NAG assay. Changes in lysosomal-related genes were measured by RT-PCR. In vivo anti-NSCLC cancer effects were assessed using C57BL/6 mice bearing Lewis tumor xenografts. FINDINGS: We identified SA-49 as a new regulator of PD-L1 expression from a series of novel aloperine derivatives. SA-49 decreased the expression of PD-L1 in NSCLC cells and enhanced the cytotoxicity of co-cultured T and NK cells toward tumor cells. Importantly, lysosomal pathway contributed to SA-49-mediated down-regulation of PD-L1. SA-49 increased the biogenesis of lysosome and promoted translocation of PD-L1 to lysosome for proteolysis, which was associated with nuclear translocation of MITF. SA-49-induced MITF translocation acted through activation of PKCα and subsequently suppression of GSK3β activity. Furthermore, SA-49 suppressed Lewis tumor xenograft growth by activating immune microenvironment in C57BL/6 mice. INTERPRETATION: Our data demonstrate that SA-49 can be used to regulate PD-L1 in cancer cells and trigger its degradation by activating lysosome function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“Cancer cells often escape immune surveillance by manipulating the expression of immune checkpoint molecules on cancer or matrix cells [1].”
BackgroundNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · cited 1×
“PD-L1 acts as a T-cell inhibitory checkpoint molecule which can inactivate tumor-infiltrating immune cells that express cell surface programmed death-1 (PD-1, also known as CD279) [4,5].”
BackgroundNutrient-sensing mechanisms and pathways
Efeyan, A., Comb, W. C., & Sabatini, D. M. (2015) · Nature · doi:10.1038/nature14190 · Cited by 1,110 · cited 1×
“Lysosomes are cytoplasmic membrane-enclosed organelles containing hydrolytic enzymes that play crucial role in degrading macromolecules and cell components [41,42].”
BackgroundCMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · cited 2×
“3f), which is consistent with previous reports that PD-L1 exerts both the proteasome[29,30] and lysosome-dependent [31] degradation pathways.”
BackgroundResultSelf-citationMITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
Ploper, D., Taelman, V. F., Robert, L., Perez, B. S., Titz, B., Chen, H.-W., Graeber, T. G., von Euw, E., Ribas, A., & De Robertis, E. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424576112 · Cited by 228 · cited 3×
“Our results are in agreement with recent reports that GSK3β inactivation promotes TFEB nuclear translocation [34].”
BackgroundResultProtein breakdown in cancer cachexia
Sandri, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.11.002 · Cited by 134 · cited 1×
“At least two systems exist for protein degradation, including the ubiquitin- proteasome and lysosomal pathways [28].”
Background
Cited by
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
PD-L1 degradation pathway and immunotherapy for cancer
Gou, Q., Dong, C., Xu, H., Khan, B., Jin, J., Liu, Q., Shi, J., & Hou, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03140-2 · Cited by 322
Emerging role of natural products in cancer immunotherapy
Dong, S., Guo, X., Han, F., He, Z., & Wang, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.020 · Cited by 278
Liu, Y., Liu, X., Zhang, N., Yin, M., Dong, J., Zeng, Q., Mao, G., Song, D., Liu, L., & Deng, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.014 · Cited by 237
Self-citationTargeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
“Since lysosomal dysfunction is closely correlated with weakened immune signals in the cancer immune response, growing attention has been paid to improving the cancer immune response by targeting disturbed lysosomal degradation.15,16,292 While CMTM6 was reported to prevent the lysosomal degradation of PD-L1, which cont…”
BackgroundInfluential
Metadata
- Authors
- Zhang, N., Dou, Y., Liu, L., Zhang, X., Liu, X., Zeng, Q., Liu, Y., Yin, M., Liu, X., Deng, H., & Song, D.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 40
- Pages
- 151-162
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2914009212
- Cited by
- 74
- References
- 11
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. https://app.cochat.ai/papers/10.1016/j.ebiom.2019.01.054
- The paper
- Zhang, N., Dou, Y., Liu, L., Zhang, X., Liu, X., Zeng, Q., Liu, Y., Yin, M., Liu, X., Deng, H., & Song, D. (2019). SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine. https://doi.org/10.1016/j.ebiom.2019.01.054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.